Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT03968419 |
Title | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) |
Acronym | CANOPY-N |
Recruitment | Terminated |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Novartis Pharmaceuticals |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | NLD | FRA | ESP | DEU | CAN | BEL |